$ALNY
ALNYLAM PHARMACEUTICALS, INC.

2018 Q4 Form 10-Q Financial Statement

#000156459018028070 Filed on November 07, 2018

View on sec.gov

Income Statement

Concept 2018 Q4 2018 Q3 2017 Q3
Revenue $21.03M $2.069M $17.10M
YoY Change -44.54% -87.9% 24.79%
Cost Of Revenue $1.700M $137.0K
YoY Change
Gross Profit $19.40M $1.932M
YoY Change
Gross Profit Margin 92.24% 93.38%
Selling, General & Admin $108.7M $116.5M $47.60M
YoY Change 61.04% 144.84% 112.5%
% of Gross Profit 560.31% 6032.35%
Research & Development $131.0M $139.9M $95.30M
YoY Change 11.21% 46.85% -2.69%
% of Gross Profit 675.26% 7243.53%
Depreciation & Amortization -$2.300M $3.300M $3.600M
YoY Change -162.16% -8.33% 2.86%
% of Gross Profit -11.86% 170.81%
Operating Expenses $239.7M $256.5M $142.9M
YoY Change 29.41% 79.49% 18.76%
Operating Profit -$220.3M -$254.6M -$125.8M
YoY Change 102.35% 17.93%
Interest Expense $10.60M $6.800M $3.300M
YoY Change 152.38% 106.06% 50.0%
% of Operating Profit
Other Income/Expense, Net -$1.300M $9.721M $2.863M
YoY Change -262.5% 239.54% 9.9%
Pretax Income -$211.1M -$244.8M -$122.9M
YoY Change 48.45% 99.16% 18.1%
Income Tax $400.0K $445.0K
% Of Pretax Income
Net Earnings -$211.4M -$245.3M -$122.9M
YoY Change 48.66% 99.52% 18.13%
Net Earnings / Revenue -1005.28% -11855.1% -719.1%
Basic Earnings Per Share
Diluted Earnings Per Share -$2.091M -$2.434M -$1.339M
COMMON SHARES
Basic Shares Outstanding 101.0M
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q4 2018 Q3 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.083B $1.222B $948.3M
YoY Change -35.94% 28.84% 35.56%
Cash & Equivalents $420.1M $316.6M $202.0M
Short-Term Investments $662.8M $905.2M $746.2M
Other Short-Term Assets $73.70M $90.80M $30.40M
YoY Change 83.79% 198.68% 57.51%
Inventory $24.07M $11.08M
Prepaid Expenses
Receivables $18.76M $3.362M $14.60M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $1.201B $1.342B $993.4M
YoY Change -31.96% 35.11% 32.88%
LONG-TERM ASSETS
Property, Plant & Equipment $320.7M $272.7M $161.9M
YoY Change 76.28% 68.44% 118.14%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $51.50M
YoY Change -84.84%
Other Assets $8.623M $60.90M $1.471M
YoY Change 106.74% 4040.04% -5.77%
Total Long-Term Assets $374.1M $333.6M $364.9M
YoY Change 62.66% -8.59% -35.45%
TOTAL ASSETS
Total Short-Term Assets $1.201B $1.342B $993.4M
Total Long-Term Assets $374.1M $333.6M $364.9M
Total Assets $1.575B $1.676B $1.358B
YoY Change -21.05% 23.37% 3.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $59.71M $21.80M $9.239M
YoY Change 110.57% 135.96% -60.07%
Accrued Expenses $112.7M $93.60M $51.26M
YoY Change 56.11% 82.6% 41.56%
Deferred Revenue $3.496M $3.444M
YoY Change -91.62%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $179.5M $121.5M $101.0M
YoY Change 24.43% 20.24% 23.59%
LONG-TERM LIABILITIES
Long-Term Debt $30.00M $30.00M $150.0M
YoY Change 0.0% -80.0% 0.0%
Other Long-Term Liabilities $4.965M $46.00M $2.842M
YoY Change 14.22% 1518.58% 42.74%
Total Long-Term Liabilities $4.965M $76.00M $2.842M
YoY Change 14.22% 2574.17% 42.74%
TOTAL LIABILITIES
Total Short-Term Liabilities $179.5M $121.5M $101.0M
Total Long-Term Liabilities $4.965M $76.00M $2.842M
Total Liabilities $272.8M $197.5M $299.4M
YoY Change 19.51% -34.04% 0.5%
SHAREHOLDERS EQUITY
Retained Earnings -$2.841B -$2.005B
YoY Change 32.28% 29.9%
Common Stock $4.176B $3.098B
YoY Change 5.76% 19.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.302B $1.478B $1.059B
YoY Change
Total Liabilities & Shareholders Equity $1.575B $1.676B $1.358B
YoY Change -21.05% 23.37% 3.46%

Cashflow Statement

Concept 2018 Q4 2018 Q3 2017 Q3
OPERATING ACTIVITIES
Net Income -$211.4M -$245.3M -$122.9M
YoY Change 48.66% 99.52% 18.13%
Depreciation, Depletion And Amortization -$2.300M $3.300M $3.600M
YoY Change -162.16% -8.33% 2.86%
Cash From Operating Activities -$150.4M -$153.8M -$98.30M
YoY Change 45.88% 56.46% 30.03%
INVESTING ACTIVITIES
Capital Expenditures -$37.50M -$45.40M -$25.70M
YoY Change 81.16% 76.65% 26.6%
Acquisitions
YoY Change
Other Investing Activities $286.4M $141.6M -$111.5M
YoY Change -304.72% -227.0% 904.5%
Cash From Investing Activities $248.9M $96.20M -$137.2M
YoY Change -254.98% -170.12% 336.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.400M 13.00M 28.90M
YoY Change -99.24% -55.02% 556.82%
NET CHANGE
Cash From Operating Activities -150.4M -153.8M -98.30M
Cash From Investing Activities 248.9M 96.20M -137.2M
Cash From Financing Activities 5.400M 13.00M 28.90M
Net Change In Cash 103.9M -44.60M -206.6M
YoY Change -76.56% -78.41% 101.36%
FREE CASH FLOW
Cash From Operating Activities -$150.4M -$153.8M -$98.30M
Capital Expenditures -$37.50M -$45.40M -$25.70M
Free Cash Flow -$112.9M -$108.4M -$72.60M
YoY Change 37.01% 49.31% 31.28%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
90843000
CY2018Q3 us-gaap Assets Current
AssetsCurrent
1342120000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
13919000
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
1988000
CY2018Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3444000
CY2017Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
41705000
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
6626000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
181900000
CY2017Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
30000000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4171000
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q3 us-gaap Inventory Net
InventoryNet
11081000
CY2018Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
101030358
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
316608000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
645361000
CY2018Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
905222000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1045257000
CY2018Q3 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
15004000
CY2018Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3362000
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
34002000
CY2017Q4 us-gaap Assets
Assets
1994730000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
28355000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
72203000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
144251000
CY2017Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
43075000
CY2017Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
30000000
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4347000
CY2017Q4 us-gaap Liabilities
Liabilities
228299000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-34433000
CY2018Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1623000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1994730000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
99666549
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
99666549
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
997000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3947552000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2147685000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
1766431000
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2069000
CY2017Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17096000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
53875000
CY2018Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
137000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
137000
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
139945000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
131910000
us-gaap Costs And Expenses
CostsAndExpenses
648192000
us-gaap Costs And Expenses
CostsAndExpenses
404773000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-125800000
us-gaap Operating Income Loss
OperatingIncomeLoss
-594317000
us-gaap Operating Income Loss
OperatingIncomeLoss
-352785000
CY2018Q3 us-gaap Investment Income Net
InvestmentIncomeNet
6796000
CY2017Q3 us-gaap Investment Income Net
InvestmentIncomeNet
3296000
us-gaap Investment Income Net
InvestmentIncomeNet
18691000
us-gaap Investment Income Net
InvestmentIncomeNet
8001000
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2925000
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-433000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5468000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3863000
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
20564000
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9721000
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2863000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
44723000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4138000
CY2018Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-244837000
CY2017Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-122937000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-549594000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-348647000
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
445000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
462000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-245282000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-122937000
us-gaap Net Income Loss
NetIncomeLoss
-550056000
us-gaap Net Income Loss
NetIncomeLoss
-348647000
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.43
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.34
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.48
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.93
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
100783000
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
91828000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
100430000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
88672000
CY2018Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
415000
CY2017Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
218000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1041000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2194000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-1894000
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-244867000
CY2017Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-122719000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-549015000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-348947000
us-gaap Profit Loss
ProfitLoss
-550056000
us-gaap Profit Loss
ProfitLoss
-348647000
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
8663000
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
9653000
us-gaap Share Based Compensation
ShareBasedCompensation
129779000
us-gaap Share Based Compensation
ShareBasedCompensation
65702000
alny Non Cash Gain On Litigation Settlement
NonCashGainOnLitigationSettlement
10000000
us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
3612000
us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
1735000
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
5004000
us-gaap Availableforsale Securities Gross Realized Gain Loss Excluding Other Than Temporary Impairments
AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments
-1894000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
608000
us-gaap Payments For Proceeds From Tenant Allowance
PaymentsForProceedsFromTenantAllowance
-11597000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-30640000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-8690000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
10354000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
34125000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2052000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-650000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-17271000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
25242000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
5990000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-11503000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-6044000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-412159000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-279742000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
89374000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
195088000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
83481000
us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
14825000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
992385000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
512026000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
1120565000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
465734000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
23981000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-129773000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
61268000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
41600000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
355150000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
21381000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1176000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
188000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
60092000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
417943000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-328086000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8428000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
646832000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
318746000
CY2017Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
203516000
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
202045000
CY2018Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
2138000
CY2017Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1471000
us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. NATURE OF BUSINESS </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We commenced operations on June&#160;14, 2002 as a biopharmaceutical company seeking to develop and commercialize novel therapeutics based on RNA interference, or RNAi. We are focused on discovering, developing and commercializing RNAi therapeutics by establishing and maintaining a strong intellectual property position in the RNAi field, establishing strategic alliances with leading pharmaceutical and life sciences companies, generating revenues through licensing agreements, and ultimately developing and commercializing RNAi therapeutics globally, either independently or with our strategic partners. We have devoted substantially all of our efforts to business planning, research, development and early commercial efforts, acquiring, filing and expanding intellectual property rights, recruiting management and technical staff, and raising capital. In late 2017, we filed a new drug application, or NDA, and a marketing authorisation application, or MAA, seeking regulatory approval of ONPATTRO<sup style="font-size:85%; vertical-align:top">TM</sup> (patisiran), our first product, in the United States and Europe, respectively. We received approval of ONPATTRO<sup style="font-size:85%; vertical-align:top"> </sup>from the United States Food and Drug Administration, or FDA, on August 10, 2018 and began commercializing and generating product revenues in the United States in August 2018. On August 30, 2018, we received approval of ONPATTRO from the European Commission, or EC, and began commercializing and generating product revenues outside of the United States in October 2018 following the launch of ONPATTRO in Germany.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to risks common to companies in our industry including, but not limited to, uncertainties relating to conducting clinical research and development, the manufacture and supply of products for clinical and commercial use, obtaining and maintaining regulatory approvals and pricing and reimbursement for our products, market acceptance, managing global growth and operating expenses, availability of additional capital, competition, obtaining and enforcing patents, stock price volatility, dependence on collaborative relationships and third-party service providers, dependence on key personnel, potential litigation, product liability claims and government investigations. </p></div>
alny Reclassification Adjustment From Aoci For Available For Sale Debt Securities
ReclassificationAdjustmentFromAOCIForAvailableForSaleDebtSecurities
0
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. In our condensed consolidated financial statements, there are significant estimates and assumptions related to our inventory valuation and related reserves, income taxes, revenue recognition, research and development expenses, and stock-based compensation.&nbsp;&nbsp;We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. Actual results could differ from those estimates.</p></div>
alny Reclassification Adjustment From Aoci For Available For Sale Debt Securities
ReclassificationAdjustmentFromAOCIForAvailableForSaleDebtSecurities
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12692000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12064000
CY2017Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
6440000
CY2017Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
125.00
CY2017Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
20500000
CY2017Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5000000
CY2017Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
71.87
CY2017Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
355200000
CY2017Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
4200000
us-gaap Stockholders Equity Period Increase Decrease
StockholdersEquityPeriodIncreaseDecrease
-288300000
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
alny Investments Classified As Cash And Cash Equivalent Original Maturities
InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities
P90D
alny Investment Maturity Period Minimum
InvestmentMaturityPeriodMinimum
P90D
alny Impairment Of Capitalized Inventory
ImpairmentOfCapitalizedInventory
0
CY2018Q3 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
0
us-gaap Revenue Performance Obligation Description Of Returns And Other Similar Obligations
RevenuePerformanceObligationDescriptionOfReturnsAndOtherSimilarObligations
ONPATTRO may be returned if it is damaged, defective or expired, with “expired” defined as having three months or less to expiry or within three months past expiry.
CY2018Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
5067000
CY2018Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
16570000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
14953000
CY2018Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
4789000
CY2018Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
6213000
CY2018Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
79000
CY2018Q3 alny Zero Cost Inventory
ZeroCostInventory
21300000
CY2018Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
905822000
CY2018Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
12000
CY2018Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
612000
CY2018Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
905222000
CY2017Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1060817000
CY2017Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
12000
CY2017Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1653000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1059176000
CY2018Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
905822000
CY2018Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
905222000
CY2018Q2 alny Litigation Settlement Common Stock Issuable From Other Party
LitigationSettlementCommonStockIssuableFromOtherParty
983208
alny Tax Cuts And Jobs Act Of2017 Measurement Period Adjustment Income Tax Expense Benefit
TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit
-800000
us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
1300000

Files In Submission

Name View Source Status
0001564590-18-028070-index-headers.html Edgar Link pending
0001564590-18-028070-index.html Edgar Link pending
0001564590-18-028070.txt Edgar Link pending
0001564590-18-028070-xbrl.zip Edgar Link pending
alny-10q_20180930.htm Edgar Link pending
alny-20180930.xml Edgar Link completed
alny-20180930.xsd Edgar Link pending
alny-20180930_cal.xml Edgar Link unprocessable
alny-20180930_def.xml Edgar Link unprocessable
alny-20180930_lab.xml Edgar Link unprocessable
alny-20180930_pre.xml Edgar Link unprocessable
alny-ex101_251.htm Edgar Link pending
alny-ex102_250.htm Edgar Link pending
alny-ex311_9.htm Edgar Link pending
alny-ex312_11.htm Edgar Link pending
alny-ex321_10.htm Edgar Link pending
alny-ex322_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gowu2sy3tvak000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending